Clinical Characteristics and Prognostic Model Analysis of Elderly Patients With Hodgkin Lymphoma in China
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.
The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥60 years
- •Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma
- •Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy
- •Availability of complete clinical, pathological, and follow-up data
排除标准
- •Presence of other malignant tumors
- •Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate <30 mL/min)
- •Missing more than 20% of required clinical data
研究组 & 干预措施
Elderly patients with Hodgkin lymphoma
Observational Cohort
结局指标
主要结局
Overall Survival (OS)
时间窗: From date of diagnosis until death from any cause, assessed up to 60 months.
Overall survival (OS) is defined as the time from diagnosis to death from any cause.
次要结局
- Progression-Free Survival (PFS)(From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months.)
- Disease-Free Survival (DFS)(From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months.)
- Event-Free Survival (EFS)(From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months.)
- Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24)(From date of diagnosis to 24 months after diagnosis.)
研究者
Huilai Zhang
Director of lymphoma department
Tianjin Medical University Cancer Institute and Hospital